GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-20. Numbers and descriptions here follow the published literature rather than marketing material.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Located on pituitary somatotroph cells |
| Signaling route | cAMP–protein kinase A | Gs-coupled receptor pathway |
| Downstream markers | Growth hormone and IGF-1 | Used as pharmacodynamic readouts |
| Common detection | LC-MS/MS | Separates intact peptide from fragments |
| Typical storage | 2–8 °C, protected from light | Applies to solid form before reconstitution |
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
== History == Insulin degludec has been filed for registration in the United States. After the completion of additional cardiac safety studies requested by the US Food and Drug Administration (FDA) in February 2013, it received FDA approval in September 2015 and marketing began in January 2016.
He commented on the blame for the war, "We might claim that Georgia initiated the war … but it appears at first impression more like a situation when somebody spits in your face twenty days on and finally you react by slapping that person back. Suddenly, the provocateur blames you for the overreaction and says, ‘I have only spit on you but I never hit you…." He further stated, "Russia was the first to breach the 1994 agreement that was negotiated. South Ossetia did not have right to keep heavy artillery on its territory under the terms of this agreement." In October 2008, Russian military expert Vladislav Shurygin wrote that Russia won the war because "the troops and headquarters were preparing for this war" since Spring 2008 when the General Staff began to plan an "operation to force Georgia to peace" and "these tasks were worked out in the spring and summer exercises of the North Caucasus Military District". He continued, "We won because at the staff offices of all levels, there were developed detailed plans in case of the outbreak of this war. [...] We won because in the chaos of muddle and confusion there were those who took responsibility. Who, in the absence of intelligible and clear instructions from Moscow, decided to begin to act according to the plans that were worked out." Shurygin concluded that "had we missed another 2-3 hours, Tskhinvali would have fallen, Georgians would cut off the Transcaucasian Highway".
As of 2010, there was widespread controversy over the use of human embryonic stem cells. This controversy primarily targets the techniques used to derive new embryonic stem cell lines, which often requires the destruction of the blastocyst. Opposition to the use of human embryonic stem cells in research is often based on philosophical, moral, or religious objections. There is other stem cell research that does not involve the destruction of a human embryo, and such research involves adult stem cells, amniotic stem cells, and induced pluripotent stem cells. In January 2009, the US Food and Drug Administration gave clearance to Geron Corporation for the first clinical trial of an embryonic stem-cell-based therapy on humans. The trial aimed to evaluate the drug GRNOPC1, embryonic stem cell-derived oligodendrocyte progenitor cells, on people with acute spinal cord injury. The trial was discontinued in November 2011 so that the company could focus on therapies in the "current environment of capital scarcity and uncertain economic conditions". In 2013 biotechnology and regenerative medicine company BioTime (AMEX: BTX) acquired Geron's stem cell assets in a stock transaction, with the aim of restarting the clinical trial.
=== Australia === A study by the Australian National University published in 2022 for Food Standards Australia New Zealand estimated there are 4.67 million cases of food poisoning in Australia each year that result in 47,900 hospitalisations, 38 deaths and a cost to the economy of $2.1 billion. A previous study using different methodology and published in November 2014, found in 2010 that there were an estimated 4.1 million cases of foodborne gastroenteritis acquired in Australia on average each year, along with 5,140 cases of non-gastrointestinal illness. The main causes were norovirus, pathogenic Escherichia coli, Campylobacter spp. and non-typhoidal Salmonella spp., although the causes of approximately 80% of illnesses were unknown. Approximately 25% (90% CrI: 13%–42%) of the 15.9 million episodes of gastroenteritis that occur in Australia were estimated to be transmitted by contaminated food. This equates to an average of approximately one episode of foodborne gastroenteritis every five years per person. Data on the number of hospitalisations and deaths represent the occurrence of serious foodborne illness. Including gastroenteritis, non-gastroenteritis and sequelae, there were an estimated annual 31,920 (90% CrI: 29,500–35,500) hospitalisations due to foodborne illness and 86 (90% CrI: 70–105) deaths due to foodborne illness circa 2010. This study concludes that these rates are similar to recent estimates in the US and Canada. A main aim of this study was to compare if foodborne illness incidence had increased over time.
=== Marriage and family === Freeman was married to Jeanette Adair Bradshaw from October 22, 1967, until November 18, 1979. He married Myrna Colley-Lee on June 16, 1984, the couple separated in December 2007 and divorced on September 15, 2010. Freeman has four children: Alfonso, Deena, Morgana, and Saifoulaye. Freeman and Colley-Lee also raised Freeman's step-granddaughter from his first marriage, E'dena Hines. On August 16, 2015, 33-year-old Hines was murdered in New York City.
Sources: en.wikipedia.org
==== TP0126 ==== The TP0126 protein has been linked to the outer membrane protein family (OMP). This protein will sit in the outer membrane like a porin, which is supported by circular dichroism recombinant TP0126, and will increase the virulence factor. Researchers have classified the TP0126 protein in this class due to the homology between the protein and the porins of the OMPs. This protein is encoded by the TP0126 gene, which is conserved over all strains of T. pallidum.
The molecular mass (m) is the mass of a given molecule, often expressed in units of daltons (Da). Different molecules of the same compound may have different molecular masses because they contain different isotopes of an element. The derived quantity relative molecular mass is the unitless ratio of the mass of a molecule to the atomic mass constant (which is equal to one dalton). The molecular mass and relative molecular mass are distinct from but related to the molar mass. The molar mass is defined as the mass of a given substance divided by the amount of the substance, and is expressed in grams per mole (g/mol). That makes the molar mass an average of many particles or molecules (weighted by abundance of the isotopes), and the molecular mass the mass of one specific particle or molecule. The molar mass is usually the more appropriate quantity when dealing with macroscopic (weigh-able) quantities of a substance. The definition of molecular weight is most authoritatively synonymous with relative molecular mass, which is dimensionless; however, in common practice, use of this terminology is highly variable. When the molecular weight is given with the unit Da, it is frequently as a weighted average (by abundance) similar to the molar mass but with different units. In molecular biology and biochemistry, the mass of macromolecules is referred to as their molecular weight and is expressed in kilodaltons (kDa), although the numerical value is often approximate and representative of an average.
The first refrigerator to see widespread use was the General Electric "Monitor-Top" refrigerator introduced in 1927, so-called, by the public, because of its resemblance to the gun turret on the ironclad warship USS Monitor of the 1860s. The compressor assembly, which emitted a great deal of heat, was placed above the cabinet, and enclosed by a decorative ring. Over a million units were produced. As the refrigerating medium, these refrigerators used either sulfur dioxide, which is corrosive to the eyes and may cause loss of vision, painful skin burns and lesions, or methyl formate, which is highly flammable, harmful to the eyes, and toxic if inhaled or ingested. The introduction of Freon in the 1920s expanded the refrigerator market during the 1930s and provided a safer, low-toxicity alternative to previously used refrigerants. Separate freezers became common during the 1940s; the term for the unit, popular at the time, was deep freeze. These devices, or appliances, did not go into mass production for use in the home until after World War II. The 1950s and 1960s saw technical advances like automatic defrosting and automatic ice making. More efficient refrigerators were developed in the 1970s and 1980s, even though environmental issues led to the banning of very effective (Freon) refrigerants. Early refrigerator models (from 1916) had a cold compartment for ice cube trays.
In late 1988, tensions between the United States and Panama were extremely high with the Panamanian leader, Manuel Noriega, calling for the dissolution of the agreement that allowed the United States to have bases in his country. In December 1989 President George H. W. Bush activated the planning section for Operation Just Cause/Promote Liberty. Just Cause was the portion of the mission to depose Noriega and return Panama to democracy. Originally scheduled to begin at 0200 hrs. on 20 December, it actually kicked off at 2315 hrs when part of a Special Forces detachment that was waiting for the signal to begin was discovered above a gate above a Panamanian checkpoint. Just Cause was the first mission to have a very large contingent of Special Operations Forces on the ground. The units that were involved with the mission were as follows: Task Force Green (Delta Force), Task Force Black (7th SFG), 5th SFG, 3rd SFG, 4th PSYOP Group, the reinforced 1st Brigade of the 82nd Airborne Division, and all three battalions of the 75th Rangers, and numerous other units from other forces such as the Navy SEALs, Marine Force Recon, and Air Force Combat Control Teams. Of the 23 US troops who died in the invasion four were Navy SEALs. The invasion was successful at deposing Noriega, but led to widespread looting and lawlessness in the following weeks.
In 2008 a Congressional mandate called for investigators funded by the NIH to submit an electronic version of their final manuscripts to the National Library of Medicine's research repository, PubMed Central (PMC), no later than 12 months after the official date of publication. The NIH Public Access Policy was the first public access mandate for a U.S. public funding agency.
Sources: en.wikipedia.org
== Pharmacology == JDTic is a potent KOR antagonist, and is highly selective for KOR over μ- (MOR) and δ-opioid receptors (DOR), along with many non-opioid receptors. However, it shows modest affinity for the nociceptin receptor (NOP). In one study, JDTic showed little binding selectivity over the μ-opioid receptor, but it failed to block the effects of the selective μ-opioid receptor agonist sufentanil across a wide range of doses in animals. It has a very long duration of action, with effects in animals seen for up to several weeks after administration of a single dose, although its binding to the KOR is not irreversible; its long duration of action is instead caused by activation of a c-Jun N-terminal kinase. Animal studies suggest that JDTic may produce antidepressant, anxiolytic, and anti-stress effects, as well as having possible application in the treatment of addiction to cocaine and morphine. JDTic shows robust activity in animal models of depression, anxiety, stress-induced cocaine relapse, and nicotine withdrawal.
However, the concentrations were supraphysiological and the same may not be the case with more physiological concentrations. Cellular proliferation in the breasts is greatest in the luteal phase of the menstrual cycle, when progesterone levels are highest. It has been hypothesized that progestogens may counteract various effects of estrogens in the brain such as stimulatory and excitatory effects on neuronal activity. Progesterone moreover has a special position among progestogens concerning such actions due to its inhibitory neurosteroid metabolites and their central depressant effects. It has been suggested that these actions of progestogens may explain unfavorable effects on mood that have been reported with these medications in some women. However, the mutual interactions of estrogens and progestogens in the brain in general are controversial and require more research. Progesterone can produce body-wide antiestrogenic effects at very high doses in both women and men via its antigonadotropic effects and consequent suppression of gonadal estrogen production (see below). These antigonadotropic effects are mediated by hyperactivation of the PR.
Carbaminohemoglobin (Hb associated with CO2) Carboxyhemoglobin (Hb associated with CO) Chlorophyll (Mg heme) Complete blood count Delta globin Hemoglobinometer Hemoprotein Methemoglobin (ferric Hb, or ferrihemoglobin) Oxyhemoglobin (with diatomic oxygen, colored blood-red) Tegillarca granosa - "blood clam" Vaska's complex – iridium organometallic complex notable for its ability to bind to O2 reversibly
== Transition from plaque induced gingivitis to periodontitis == Plaque-induced gingivitis and the more severe stage plaque induced periodontitis are the most common of the periodontal diseases. While in some individuals gingivitis never progresses to periodontitis, periodontitis is always preceded by gingivitis. In 1976, Page & Schroeder introduced an innovative new analysis of periodontal disease based on histopathologic and ultrastructural features of the diseased gingival tissue. Although this new classification does not correlate with clinical signs and symptoms and is admittedly "somewhat arbitrary," it permits a focus of attention pathologic aspects of the disease that were, until recently, not well understood. This new classification divided plaque-induced periodontal lesions into four stages, namely, initial lesion, early lesion, established lesion and advanced lesion.
Sources: en.wikipedia.org
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.
IGF-1 reflects growth hormone activity but changes slowly and can be measured from one sample. Growth hormone itself is pulsatile, which makes single measurements hard to interpret.
The receptor pathway is well described, but how individual responses vary and what governs long-term outcomes remain open questions. Reported differences across studies are often attributed to assay and population factors.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.